Enhancement of immune responses to an HIV env DNA vaccine by a C-terminal segment of listeriolysin O

AIDS Research and Human Retroviruses

Volumn 19, Issue 5, 2003, Pages 409-420

  Bu, Zhigao ^a   Ye, Ling ^a   Skeen, Marianne J ^a   Ziegler, H Kirk ^a   Compans, Richard W ^a   Yang, Chinglai ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; DNA VACCINE; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LISTERIOLYSIN; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENVELOPE GENE; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; BACTERIAL TOXINS; FEMALE; HEAT-SHOCK PROTEINS; HEMOLYSIN PROTEINS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; IMMUNIZATION; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PLASMIDS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA;

EID: 0038521720     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922203765551755     Document Type: Article

References (44)

1. Gurunathan S, Klinman DM, and Seder RA: DNA vaccines: Immunology, application, and optimization. Annu Rev Immunol 2000;18:927-974.
2. Letvin NL, Bloom BR, and Hoffman SL: Prospects for vaccines to protect against AIDS, tuberculosis, and malaria. JAMA 2001; 285:606-611.
3. Nabel GJ: Challenges and opportunities for development of an AIDS vaccine. Nature 2001;410:1002-1007.
4. Amara RR, Villinger F, Altman JD, Lydy SL, O'Nell SP, Staprans SI, Montefiori DC, Xu Y, Herndon JG, Wyatt LS, Candido MA, Kozyr NL, Earl PL, Smith JM, Ma HL, Grimm BD, Hulsey M, Miller J, McClure HM, McNicholl JM, Moss B, and Robinson HL: Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001;292:69-74.
5. Barouch DH, Craiu A, Kuroda MJ, Schmitz JE, Zheng XX, Santra S, Frost JD, Krivulka GR, Lifton MA, Crabbs CL, Heidecker G, Perry HC, Davies ME, Xie H, Nickerson CE, Steenbeke TD, Lord CI, Montefiori DC, Strom TB, Shiver JW, Lewis MG, and Letvin NL: Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci USA 2000;97: 4192-4197.
6. Montefiori DC, Safrit JT, Lydy SL, Barry AP, Bilska M, Vo HT, Klein M, Tartaglia J, Robinson HL, and Rovinski B: Induction of neutralizing antibodies and Gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques. J Virol 2001;75:5879-5890.
7. Shedlock DJ and Weiner DB: DNA vaccination: Antigen presentation and the induction of immunity. J Leukoc Biol 2000;68: 793-806.
8. Dupuis M, Denis-Mize K, Woo C, Goldbeck C, Selby MJ, Chen M, Otten GR, Ulmer JB, Donnelly JJ, Ott G, and McDonald DM: Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol 2000;165:2850-2858.
9. Gaillard JL, Berche P, and Sansonetti P: Transposon mutagenesis as a tool to study the role of hemolysin in the virulence of Listeria monocytogenes. Infect Immun 1986;52:50-55.
10. + T cells requires secretion of hemolysin and intracellular bacterial growth. J Immunol 1990;145:3540-3546.
11. Hiltbold EM, Safley SA, and Ziegler HK: The presentation of class I and class II epitopes of listeriolysin O is regulated by intracellular localization and by intercellular spread of Listeria monocytogenes. J Immunol 1996;157:1163-1175.
12. Haas J, Park EC, and Seed B: Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr Biol 1996;6:315-324.
13. Skeen MJ, Rix EP, Freeman MM, and Ziegler HK: Exaggerated proinflammatory and Th1 responses in the absence of γ/δ T cells after infection with Listeria monocytogenes. Infect Immun 2001; 69:7213-7223.
14. Uchijima M, Yoshida A, Nagata T, and Koide YJ: Optimization of codon usage of plasmid DNA vaccine is required for the effective MHC class I-restricted T cell responses against an intracellular bacterium. J Immunol 1998;161:5594-5599.
15. Corbet S, Vinner L, Hougaard DM, Bryder K, Nielsen HV, Nielsen C, and Fomsgaard A: Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons. AIDS Res Hum Retroviruses 2000;16:1997-2008.
16. Tweten RK, Parker MW, and Johnson AE: The cholesterol-dependent cytolysins. Curr Top Microbiol Immunol 2001;257:15-33.
17. Romagnani S: The Th1/Th2 paradigm. Immunol Today 1997;18: 263-266.
18. 1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci USA 1996;93:5141-5145.
19. Jones S, Preiter K, and Portnoy DA: Conversion of an extracellular cytolysin into a phagosome-specific lysin which supports the growth of an intracellular pathogen. Mol Microbiol 1996;21: 1219-1225.
20. Geoffroy C, Gaillard JL, Alouf JE, and Berche P: Purification, characterization, and toxicity of the sulfhydryl-activated hemolysin listeriolysin O from Listeria monocytogenes. Infect Immun 1987;55: 1641-1646.
21. Willey RL, Bonifacino JS, Ports BJ, Martin MA, and Klausner RD: Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. Proc Natl Acad Sci USA 1988;85:9580-9584.
22. Chapman HA: Endosomal proteolysis and MHC class II function. Curr Opin Immunol 1998;10:93-102.
23. + human immunodeficiency virus type 1 (HIV-1) envelope-specific cytotoxic T lymphocytes derived from the peripheral blood cells of an HIV-1-infected individual. AIDS Res Hum Retroviruses 1993;9:61-68.
24. + T-cell clones. J Virol 2001;75:9771-9779.
25. + T cell responses associated with control of viremia. Science 1997; 278:1447-1450.
26. + T-cell clones from an HIV-1-seronegative donor following in vitro immunization. J Virol 2002;76: 6987-6999.
27. + T cell responses during chronic virus infection prevents neutralizing antibody responses against virus escape mutants. J Exp Med 2001;193:297-305.
28. + cytotoxic T-cell responses during chronic viral infection. J Virol 1994;68:8056-8063.
29. + T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: Implications for adoptive immunotherapy of virus carriers. Proc Natl Acad Sci USA 1997;94:6874-6879.
30. + T cells. Curr Opin Immunol 1998;10:444-449.
31. Franco A, Tilly DA, Gramaglia I, Croft M, Cipolla L, Meldal M, and Grey HM: Epitope affinity for MHC class I determines helper requirement for CTL priming. Nat Immunol 2000;1:145-150.
32. Barouch DH, Kunstman J, Kuroda MJ, Schmitz JE, Santra S, Peyerl FW, Krivulka GR, Beaudry K, Lifton MA, Gorgone DA, Montefiori DC, Lewis MG, Wolinsky SM, and Letvin NL: Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002;415:335-339.
33. Krieg AM: CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002;20:709-760.
34. Moldoveanu Z, Love-Homan L, Huang WQ, and Krieg AM: CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 1998;16:1216-1224.
35. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, and Krieg AM: Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 1997;94:10833-10837.
36. Deml L, Bojak A, Steck S, Graf M, Wild J, Schirmbeck R, Wolf H, and Wagner R: Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. J Virol 2001;75:10991-11001.
37. Haas J, Park EC, and Seed B: Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr Biol 1996;6:315-324.
38. zur Megede J, Chen MC, Doe B, Schaefer M, Greer CE, Selby M, Otten GR, and Barnett SW: Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene. J Virol 2000;74:2628-2635.
39. Uchijima M, Yoshida A, Nagata T, and Koide YJ: Optimization of codon usage of plasmid DNA vaccine is required for the effective MHC class I-restricted T cell responses against an intracellular bacterium. J Immunol 1998;161:5594-5599.
40. Tsuji T, Hamajima K, Fukushima J, Xin KQ, Ishii N, Aoki I, Ishigatsubo Y, Tani K, Kawamoto S, Nitta Y, Miyazaki J, Koff WC, Okubo T, and Okuda K: Enhancement of cell-mediated immunity against HIV-1 induced by coinoculation of plasmid-encoded HIV-1 antigen with plasmid expressing IL-12. J Immunol 1997; 158:4008-4013.
41. Kim JJ, Bagarazzi ML, Trivedi N, Hu Y, Kazahaya K, Wilson DM, Ciccarelli R, Chattergoon MA, Dang K, Mahalingam S, Chalian AA, Agadjanyan MG, Boyer JD, Wang B, and Weiner DB: Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat Biotechnol 1997; 15:641-646.
42. Iwasaki A, Stiernholm BJ, Chan AK, Berinstein NL, and Barber BH: Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol 1997;158:4591-4601.
43. Chattergoon MA, Kim JJ, Yang JS, Robinson TM, Lee DJ, Dentchev T, Wilson DM, Ayyavoo V, and Weiner DB: Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis. Nat Biotechnol 2000;18:974-979.
44. Sasaki S, Amara RR, Oran AE, Smith JM, and Robinson HL: Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases. Nat Biotechnol 2001;19:543-547.